Imago BioSciences, Inc.

UPDATE – PharmaEssentia has corrected the press release issued 6 January about the Phase III results for Besremi in essential thrombocytopenia to note the incidence of two treatment-related serious ad

Merck & Co., Inc. helped reshape the way that many cancer patients are treated by bringing forward an immunotherapy that improved survival and reduced cancer recurrence across multiple aggressive tum

Merck & Co., Inc. CEO Rob Davis said the Inflation Reduction Act’s (IRA) drug-pricing policies are already affecting the company's R&D and business development decisions. Davis talked about grappling

When Merck & Co., Inc. chief medical officer and head of global clinical development Eliav Barr took over the position from Roy Baynes earlier this year, it was the latest transition in a broader le